Aaron S. Farberg, MD

A panelist discusses how the rise of convenient and accessible oral therapies is poised to redefine systemic treatment strategies, payer decisions, and clinical guidelines in dermatology.

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

Panelists discuss how the future of generalized pustular psoriasis (GPP) diagnosis and management looks promising with emerging genetic testing for IL36RN mutations, development of multiple targeted biologics beyond IL-36 inhibitors, potential personalized treatment algorithms, improved disease classification, and enhanced multidisciplinary care approaches to better address this rare but severe dermatological condition.

Panelists discuss how a high-risk patient with generalized pustular psoriasis requires a carefully tailored treatment approach that balances aggressive intervention to control acute flares with consideration of comorbidities, medication interactions, and long-term safety concerns, often necessitating multidisciplinary collaboration between dermatologists, intensivists, and other specialists.

Panelists discuss how poorly managed generalized pustular psoriasis (GPP) flares can lead to recurrent hospitalizations and significant morbidity, while reviewing Effisayil 2 trial results that demonstrated the effectiveness of maintenance therapy in preventing flares and sustaining long-term disease control through targeted inhibition of the IL-36 pathway.

Panelists discuss how a generalized pustular psoriasis (GPP) emergency case highlights the rapid onset, systemic complications, and treatment challenges of this condition, while reviewing Effisayil 1 trial results that demonstrated spesolimab’s efficacy in quickly resolving pustulation through IL-36 pathway inhibition, representing a significant advancement in targeted therapy for acute flares.

Panelists discuss how prior and current treatments for patients with generalized pustular psoriasis (GPP) have evolved from traditional systemic therapies with significant limitations to newer targeted biologics and small molecules that specifically address the underlying IL-36 pathway dysregulation, offering improved efficacy and safety profiles for this rare but severe condition.

Panelists discuss how recognizing the flares and triggers of generalized pustular psoriasis requires vigilant monitoring for warning signs such as fever, malaise, and spreading erythema, while understanding that common precipitating factors include medication withdrawals, infections, pregnancy, and certain drugs that can rapidly transform stable disease into acute, potentially life-threatening episodes requiring immediate intervention.

Aaron Farberg, MD, discuss how to educate parents about the potential adverse effects of a new therapy while also reassuring them about its overall safety profile by providing clear, evidence-based information and emphasizing the rigorous testing and monitoring processes.

Aaron Farberg, MD, discuss how appropriate monitoring, including regular assessments of growth, potential side effects, and laboratory tests to evaluate liver function and hematologic parameters, would be necessary when prescribing a topical JAK inhibitor to a younger child (age 2-11 years).

Aaron Farberg, MD, discuss how JAK inhibitors have come under scrutiny in the past for systemic adverse effects in oral formulations, while exploring the safety data of topical JAK inhibitors in the pediatric population, which appears to show a more favorable risk profile with localized effects.

Aaron Farberg, MD, discusses how, when prescribing therapies for pediatric patients, dermatologists prioritize long-term safety alongside efficacy. Topical Janus kinase (JAK) inhibitors have demonstrated a favorable safety profile compared with their oral counterparts, with minimal systemic absorption. Appropriate monitoring may include baseline blood work and periodic clinical assessments, particularly in younger children. Effective parent education balances transparent discussion of potential adverse effects with evidence-based reassurance about the therapy’s safety profile.

Panelists discuss how generalized pustular psoriasis (GPP) profoundly impacts patients’ quality of life through physical pain, psychological distress, social isolation, and functional limitations, necessitating comprehensive support systems that address both medical management and psychosocial well-being.

Panelists discuss how the diagnosis and management of generalized pustular psoriasis present significant challenges due to its rarity, complex presentation, potentially life-threatening complications, limited treatment options, and the need for multidisciplinary care approaches.

Panelists discuss how clinical experience in diagnosing generalized pustular psoriasis (GPP) requires recognizing its hallmark features of widespread sterile pustules on inflamed skin, distinguishing it from other pustular conditions, and understanding the genetic mutations and triggers that can precipitate this rare but potentially life-threatening form of psoriasis.

Panelists discuss how generalized pustular psoriasis (GPP), while rare, presents with distinctive widespread sterile pustules on erythematous skin, requires prompt medical intervention, and differs significantly from more common plaque psoriasis in its clinical presentation, triggers, and treatment approaches.

Join Dermatology Times’ quarterly editor in chief Aaron Farberg, MD, as he highlights significant advancements in gene expression profile testing for cutaneous melanoma.

Aaron Farberg, MD, explores advancements in melanoma and cSCC prognostic tools, the role of gene expression profiling in inflammatory diseases, and initiatives aimed at supporting early-career dermatologists at Fall Clinical 2024.

Panelists discuss how red light therapy has emerged as a versatile, noninvasive treatment in aesthetic dermatology, offering benefits such as collagen stimulation and skin rejuvenation while comparing favorably with other cosmetic treatments in terms of minimal adverse effects and high patient satisfaction rates.

Panelists discuss how red light therapy accelerates wound healing by stimulating cellular energy production, increasing blood flow, reducing inflammation, and promoting collagen synthesis, leading to faster tissue repair and regeneration in various clinical scenarios.

Aaron Farberg, MD, discusses how red light therapy utilizes specific wavelengths of light to penetrate skin cells, stimulating mitochondrial function, potentially leading to various therapeutic effects such as reduced inflammation and improved tissue repair.

Farberg discusses data recently published in Geriatrics demonstrating low rates of recurrence.

Step therapy can delay appropriate care and potentially worsen patients' conditions, writes Dermatology Times Spring Editor in Chief Aaron Farberg, MD.

Dermatology Times' Spring Editor in Chief, Aaron Farberg, MD, discusses the business strategy known as buy and bill.

Farberg is looking forward to another year of top-notch presentations at Fall Clinical 2023.

Aaron Farberg, MD, and Shanna Miranti, MPAS, PA-C, discuss the upcoming approvals of nivolumab and IDP-126.

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.